Beijing-based Biotech Sager Therapeutics Raises Over RMB 600 Million in Series C Round at RMB 1.45 Billion Pre-money Valuation

Oct 04, 2025 10:03 CST Updated 10:03

Grit Biotherapeutics

Developer of Immunotherapy Drugs for Solid Tumors

▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators SummitScan to register

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

PharmaCircleMonitoring shows: Recently，Beijing Grail Bio Completes New Round of Financing. Investors include Junshi Biosciences, its partner Loyal Valley Capital, and other enterprises and funds, with an amount exceeding 600 million RMB.

Gravel BiotechIt is an innovative pharmaceutical company focusing on tumor immunocyte therapy, with a research and development pipeline represented by tumor-infiltrating lymphocyte (TIL) drugs. The self-developed GT101 injection is China's first TIL drug approved for registrational clinical trials and has now entered the pivotal Phase II clinical trial. GT201 injection, the world’s first TIL product incorporating a membrane-bound IL-15 complex, has completed dual IND applications in China and the U.S. and has been approved to enter Phase I clinical trials.

Reference:

https://pharma.bcpmdata.com；

Etc.

Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceutical industry. With the mission of "enabling the boundless flow of intelligence and connections," it has built an empowerment system covering the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industry think tanks, and ecosystem communities—it is creating infrastructure to facilitate the flow of value in China's pharmaceutical sector.

Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises’ leapfrog growth.